8-K

United States
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 25, 2007

OXiGENE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation) 0-21990
(Commission File
Number) 13-3679168
(I.R.S. Employer
Identification No.)

230 Third Avenue, Waltham, MA 02451

(Address of principal executive offices)

Registrant’s telephone number, including area code: (781) 547-5900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	ITEM 5.02   DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
	ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURE
EXHIBITS
EX-99.1 Press Release dated June 27, 2007

ITEM 5.02   DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(a)   Not applicable.

(b)   Not applicable.

(c)   Not applicable.

(d)   On June 27, 2007, OXiGENE, Inc. (“OXiGENE” or the “Company”) announced that its Board of Directors had expanded the size of the Board to nine members and appointed Roy Hampton Fickling and William D. Schwieterman, M.D. to serve as members of the Board.

Mr. Fickling, 41, is the owner and President of Fickling & Company, Inc., a Macon, Georgia-based regional real estate development, brokerage, management and consulting firm, since October 1993, and a Director of several closely held investment and operating companies. Mr. Fickling was a founding Director of Rivoli Bank & Trust, of Macon and of Beech Street, U.K., Ltd. of London, England, an international healthcare administration firm. He was a major shareholder and advisor to Beech Street Corporation, the largest private PPO network, prior to its acquisition by Concentra, Inc. in 2005. Prior to forming Fickling & Company, Mr. Fickling was employed by Charter Medical Corporation where he worked in the administration of both a medical surgical hospital and a psychiatric hospital. Mr. Fickling holds a B.A. in Business Administration from the University of Georgia.

Dr. Schwieterman, 49, has been an independent consultant to biotech and pharmaceutical companies specializing in clinical development since July 2002. He is a board-certified internist and a rheumatologist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati.

Each of Mr. Fickling and Dr. Schwieterman, similarly to the other members of the Company’s Board of Directors, will serve terms concluding at each annual meeting of the Company’s stockholders, and will receive annual compensation of $30,000 for his service as director. Each of them has also been granted 40,000 shares of the Company’s restricted common stock, vesting over four years in accordance with the terms of the applicable Restricted Stock Agreement.

(e)   Not applicable.

(f)   Not applicable.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

(d)   Exhibits:

Exhibit Number	Description
99.1	Press Release dated June 27, 2007, reporting appointment of Mr. Fickling and Dr. Schwieterman to OXiGENE’s Board of Directors.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2007	OXiGENE, Inc.
	/s/ James B. Murphy
	By: James B. Murphy Vice President and Chief Financial Officer

EXHIBITS

Exhibit Number	Description
99.1	Press Release dated June 27, 2007, reporting appointment of Mr. Fickling and Dr. Schwieterman to OXiGENE’s Board of Directors.

EX-99.1

Exhibit 99.1

CONTACT: OXiGENE, Inc.
Investor Relations, 781-547-5900
Shari Annes, 650-888-0902

OXiGENE ADDS TWO NEW DIRECTORS TO ITS BOARD

WALTHAM, Mass — June 27, 2007 — OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the Company has added two new members to its Board of Directors. The addition of Roy Hampton Fickling and William D. Schwieterman, M.D., as Directors brings the total number of OXiGENE Directors to nine.

Dr. Schwieterman is a board-certified internist and a rheumatologist, and was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the Food and Drug Administration (FDA). In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of molecules. He worked with sponsors for the development of new agents for pulmonary medicine, neurology, sepsis, hepatitis, rheumatology, infectious disease, solid organ transplantation and wound-healing, among other areas, and also worked closely with reviewers of vaccines, devices (CDRH) and oncologic products. Dr. Schwieterman also helped author the FDA’s “Good Review Practices” for investigational products, and was instrumental in the development of several guidance documents. Dr. Schwieterman is now an independent consultant to biotech and pharmaceutical companies specializing in clinical development.

Mr. Fickling is the owner and President of Fickling & Company, Inc., a Macon, GA-based regional real estate development, brokerage, management and consulting firm, and a Director of several closely held investment and operating companies. In the past, he was a founding Director of Rivoli Bank & Trust, of Macon and of Beech Street, U.K., Ltd. of London, England, an international healthcare administration firm. He was a major shareholder and advisor to Beech Street Corporation, the largest private PPO network, prior to its acquisition by Concentra, Inc. in 2005. Prior to forming Fickling & Company, Mr. Fickling was employed by Charter Medical

— more —

OXiGENE ADDS BOARD MEMBERS
p. 2
6/27/07

Corporation where he worked in the administration of both a medical surgical hospital and a psychiatric hospital.

Joel Citron, Chairman of the Board, stated, “I am pleased to welcome Mr. Fickling and Dr. Schwieterman to OXiGENE’s Board of Directors. Roy’s track record as a highly regarded businessman and his experience with the healthcare providers and payors will be an important addition to OXiGENE’s board. Bill has extensive experience at senior levels of the FDA, as well as expertise on clinical trials and regulatory strategy.”

Richard Chin, M.D., the Chief Executive Officer stated, “We look forward to working with Mr. Fickling and Dr. Schwieterman as we mature the pipeline with a goal of bringing important products to the market. Experience from the payor perspective and from the regulatory perspective will be very helpful to the company as we transition into a late clinical stage company and beyond.”

About OXiGENE, Inc.

OXiGENE is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company’s major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, including those relating to the successful completion of planned clinical trials and product approvals by the FDA may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE’s reports to the Securities and Exchange Commission, including OXiGENE’s Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

# # #